144 related articles for article (PubMed ID: 36754658)
1. [Drug approval: Crizotinib for relapsed or refractory, ALK-positive, systemic anaplastic large cell lymphoma in pediatrics].
Meurillon R; Leruste A
Bull Cancer; 2023 Mar; 110(3):250-251. PubMed ID: 36754658
[No Abstract] [Full Text] [Related]
2. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
[TBL] [Abstract][Full Text] [Related]
3. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial.
Brugières L; Cozic N; Houot R; Rigaud C; Sibon D; Arfi-Rouche J; Bories P; Cottereau AS; Delmer A; Ducassou S; Garnier N; Lamant L; Leruste A; Millot F; Moalla S; Morschhauser F; Nolla M; Pagnier A; Reguerre Y; Renaud L; Schmitt A; Simonin M; Verschuur A; Hoog Labouret N; Mahier Ait Oukhatar C; Vassal G
Eur J Cancer; 2023 Sep; 191():112984. PubMed ID: 37549532
[TBL] [Abstract][Full Text] [Related]
5. Combination of crizotinib and chemotherapy in patients with relapsed or refractory anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).
Chen MT; Fu XH; Huang H; Wang Z; Fang XJ; Yao YY; Ren QG; Chen ZG; Lin TY
Leuk Lymphoma; 2021 Mar; 62(3):571-580. PubMed ID: 33155495
[TBL] [Abstract][Full Text] [Related]
6. IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.
Prokoph N; Probst NA; Lee LC; Monahan JM; Matthews JD; Liang HC; Bahnsen K; Montes-Mojarro IA; Karaca-Atabay E; Sharma GG; Malik V; Larose H; Forde SD; Ducray SP; Lobello C; Wang Q; Luan SL; Pospíšilová Š; Gambacorti-Passerini C; Burke GAA; Pervez S; Attarbaschi A; Janíková A; Pacquement H; Landman-Parker J; Lambilliotte A; Schleiermacher G; Klapper W; Jauch R; Woessmann W; Vassal G; Kenner L; Merkel O; Mologni L; Chiarle R; Brugières L; Geoerger B; Barbieri I; Turner SD
Blood; 2020 Oct; 136(14):1657-1669. PubMed ID: 32573700
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
Ou SH
Drug Des Devel Ther; 2011; 5():471-85. PubMed ID: 22162641
[TBL] [Abstract][Full Text] [Related]
8. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
10. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
[TBL] [Abstract][Full Text] [Related]
11. Trial watch: success for crizotinib in ALK-driven cancer.
Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119722
[No Abstract] [Full Text] [Related]
12. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Kazandjian D; Blumenthal GM; Chen HY; He K; Patel M; Justice R; Keegan P; Pazdur R
Oncologist; 2014 Oct; 19(10):e5-11. PubMed ID: 25170012
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.
Kothari S; Ud-Din N; Lisi M; Coyle T
J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y
Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941
[TBL] [Abstract][Full Text] [Related]
15. The role of anaplastic lymphoma kinase inhibitors in the treatment of advanced nonsmall cell lung cancer.
D'Arcangelo M; Wynes MW; Hirsch FR
Curr Opin Oncol; 2013 Mar; 25(2):121-9. PubMed ID: 23385859
[TBL] [Abstract][Full Text] [Related]
16. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
17. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
18. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma.
Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J
Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400
[TBL] [Abstract][Full Text] [Related]
19. Treating ALK-positive lung cancer in the weeks after the FDA approval of crizotinib.
Pennell NA
Am J Manag Care; 2012 May; 18(5 Spec No. 2):SP84-7. PubMed ID: 22693986
[No Abstract] [Full Text] [Related]
20. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
